Cyramza
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
TABLE OF CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Cyramza : Non-small cell lung cancer (NSCLC)
19 Cyramza : Gastric cancer
33 Cyramza : Colorectal cancer (CRC)
47 Cyramza : Hepatocellular carcinoma (HCC)
56 Cyramza
LIST OF FIGURES
11 Figure 74: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
12 Figure 75: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
24 Figure 78: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
25 Figure 79: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
26 Figure 80: Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
28 Figure 81: Zykadia for non-small cell lung cancer – SWOT analysis
38 Figure 7: Cyramza for colorectal cancer – SWOT analysis
39 Figure 8: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
40 Figure 83: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
42 Figure 84: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
51 Figure 84: Capmatinib for non-small cell lung cancer – SWOT analysis
52 Figure 12: Datamonitor Healthcare’s drug assessment summary of Cyramza for hepatocellular carcinoma
53 Figure 85: Datamonitor Healthcare’s drug assessment summary for capmatinib in non-small cell lung cancer
59 Figure 87: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
60 Figure 88: Cemiplimab for non-small cell lung cancer – SWOT analysis
LIST OF TABLES
7 Table 1: Cyramza drug profile
8 Table 2: Cyramza pivotal trial data in non-small cell lung cancer
10 Table 3: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
15 Table 100: Vargatef patient numbers for NSCLC across the five major EU markets, by country, 2017–26
16 Table 5: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 6: Cyramza drug profile
21 Table 7: Cyramza pivotal trial data in gastric cancer
29 Table 8: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
31 Table 9: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
33 Table 10: Cyramza drug profile
35 Table 11: Cyramza Phase III data in colorectal cancer
37 Table 12: Cyramza Phase I trials in colorectal cancer
43 Table 13: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
45 Table 14: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
48 Table 15: Cyramza drug profile
49 Table 107: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
50 Table 17: Cyramza Phase III trial in HCC
50 Table 18: Cyramza Phase II data in HCC
57 Table 19: Cyramza drug profile
58 Table 20: Cyramza pivotal trial data in gastric cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the